Critically Ill Pediatric Patient and SARS-CoV-2 Infection

Jozef Klučka1,2, Eva Klabusayová1,2, Milan Kratochvíl1,2

  • 1Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.

Insights

The COVID-19 pandemic, caused by SARS-CoV-2, continues to impact both adult and pediatric intensive care units in 2022. A significant challenge remains the multisystemic inflammatory syndrome observed in children.

Area of Science:

  • Infectious Diseases
  • Pediatric Critical Care
  • Public Health

Background:

  • The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing COVID-19 pandemic starting in December 2019.
  • While initially focused on vulnerable elderly adults with comorbidities, COVID-19 significantly affects pediatric intensive care.
  • Multisystemic inflammatory syndrome in children (MIS-C) emerged as a critical post-infection complication in early 2020.

Purpose of the Study:

  • To highlight the persistent clinical challenges of COVID-19 in adult and pediatric intensive care settings in 2022.
  • To underscore the impact of SARS-CoV-2 on pediatric populations, including the emergence of MIS-C.
  • To acknowledge the ongoing threat despite available vaccinations and evolving viral landscape.

Main Methods:

  • Review of clinical data and epidemiological trends related to COVID-19.
  • Analysis of disease presentation and outcomes in adult and pediatric intensive care.
  • Monitoring of viral mutations and vaccination efficacy in the context of the pandemic.

Main Results:

  • COVID-19 remains a significant clinical challenge in intensive care units for both adults and children in 2022.
  • Pediatric intensive care has been notably impacted, with the emergence of multisystemic inflammatory syndrome in children (MIS-C).
  • Viral mutations and variable vaccination rates contribute to the ongoing clinical challenge.

Conclusions:

  • COVID-19 continues to pose a substantial threat to critical care services globally in 2022.
  • The pediatric population is significantly affected, necessitating vigilance for conditions like MIS-C.
  • Ongoing viral evolution and vaccination disparities present persistent challenges in managing the pandemic.

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
406
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
360
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
367
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
220
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
255
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
466